Hosted on MSN2mon
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b studyTryptamine’s phase 1b study of IV-infused psilocin meets all objectives ... aimed at treating patients with Binge Eating Disorder. The company said the decision followed exceptional results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results